, Feb. 20, 2014
/PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States
and, if positive, is expected to lead to the approval of AtoKin by 2015.
AtoKin is a beef-flavored, chewable, high-dose, second generation histamine H1-receptor antagonist. The active ingredient in AtoKin does not cross the brain-blood barrier and causes less drowsiness and other side effects than first generation antihistamines. The active ingredient has been widely studied in humans and is well-tolerated and effective in the treatment of allergic rhinitis. In a peer reviewed, published study of dogs with atopic dermatitis, the active ingredient in AtoKin was shown to be comparable to methylprednisolone at 3 weeks of treatment, and statistically significantly better than methylprednisolone at 6 weeks of treatment.
Richard Chin, Chief Executive Officer of Kindred Bio, stated, "We are excited to begin our second pivotal study. We believe AtoKin is on track to be approved by 2015 if this study is positive, and we look forward to providing our canine patients with relief from this often-debilitating condition."
About Kindred Biosciences
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company's lead product candidates are CereKin for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin for the treatment of atopic dermatitis in dogs, and SentiKin for the treatment of post-operative pain in dogs.
Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.
SOURCE Kindred Biosciences, Inc.